Professor Georgina Long AO

BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS

Co-Medical Director

Professor Georgina Long AO, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney.

She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.

In recognition of her ground-breaking research and work, Professor Long was recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal (2021) and was appointed as an Officer of the Order of Australia (2020) and has received several awards, including the including the prestigious Ramaciotti Medal for Biomedical Research (2021), the Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including: the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016 & 2017), and in 2013 she was named the Outstanding Cancer Research Fellow.  She is also a Clarivate Highly-Cited Researcher for 2017-2021. Her H-index is 115 and in June 2022 she was ranked the world’s 2nd, and Australia’s 1st melanoma expert in all fields and discipline. See Expertscape website.

Professor Long is the author of over 400 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Journal of Clinical Oncology and Cancer Discovery.  Professor Long has presented her work at international conferences and meetings on more than 200 occasions. She is Past President of the prestigious international Society for Melanoma Research (2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is a member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024). She is on the editorial boards  of several  high-impact  journals,  and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

To get in touch with Professor Georgina Long AO, please email her Executive Assistant at  EAlong@melanoma.org.au

Prof Long Recent News

Prof Long Recent Publications

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

2022-07-23T17:15:22+10:00November 24th, 2021|

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. J Clin Oncol. (Epub 24 Nov 2021)

|

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis.

2022-07-23T16:44:16+10:00October 21st, 2021|

Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebbé C, Enokida T, Tahara M, Bröckelmann PJ, Eigentler T, Kähler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L. Front Oncol. (21 Oct 2021)

|
Load More Posts

Go to Top